These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 18164380)

  • 1. Limited utility of conventional criteria for predicting unresectable disease in patients with advanced stage epithelial ovarian cancer.
    Salani R; Axtell A; Gerardi M; Holschneider C; Bristow RE
    Gynecol Oncol; 2008 Feb; 108(2):271-5. PubMed ID: 18164380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of bulky upper abdominal disease cephalad to the greater omentum on surgical outcome for stage IIIC epithelial ovarian, fallopian tube, and primary peritoneal cancer.
    Zivanovic O; Eisenhauer EL; Zhou Q; Iasonos A; Sabbatini P; Sonoda Y; Abu-Rustum NR; Barakat RR; Chi DS
    Gynecol Oncol; 2008 Feb; 108(2):287-92. PubMed ID: 17996927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complete surgical cytoreduction of advanced ovarian carcinoma using the argon beam coagulator.
    Bristow RE; Montz FJ
    Gynecol Oncol; 2001 Oct; 83(1):39-48. PubMed ID: 11585412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer.
    Aletti GD; Dowdy SC; Gostout BS; Jones MB; Stanhope CR; Wilson TO; Podratz KC; Cliby WA
    Obstet Gynecol; 2006 Jan; 107(1):77-85. PubMed ID: 16394043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer.
    Eisenhauer EL; Abu-Rustum NR; Sonoda Y; Levine DA; Poynor EA; Aghajanian C; Jarnagin WR; DeMatteo RP; D'Angelica MI; Barakat RR; Chi DS
    Gynecol Oncol; 2006 Dec; 103(3):1083-90. PubMed ID: 16890277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A study to evaluate the utility of presurgical CA125 to predict optimal tumor cytoreduction of epithelial ovarian cancer.
    Gilani MM; Karimi Zarchi M; Ghaemmaghami F; Behtash N; Mousavi AS; Ansaripoor S
    Gynecol Oncol; 2007 Jun; 105(3):780-3. PubMed ID: 17433423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beyond tertiary cytoreduction in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
    Shih KK; Chi DS; Barakat RR; Leitao MM
    Gynecol Oncol; 2010 Mar; 116(3):364-9. PubMed ID: 19897231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma.
    Tebes SJ; Sayer RA; Palmer JM; Tebes CC; Martino MA; Hoffman MS
    Gynecol Oncol; 2007 Sep; 106(3):482-7. PubMed ID: 17590420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [How to increase the optimal rate of secondary cytoreductive surgery in recurrent epithelial ovarian cancer].
    Li YF; Li MD; Liu FY; Liu JH; Li JD
    Ai Zheng; 2003 Nov; 22(11):1193-6. PubMed ID: 14613651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma.
    Chi DS; Venkatraman ES; Masson V; Hoskins WJ
    Gynecol Oncol; 2000 May; 77(2):227-31. PubMed ID: 10785469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What are the current surgical objectives, strategies, and technical capabilities of gynecologic oncologists treating advanced epithelial ovarian cancer?
    Eisenkop SM; Spirtos NM
    Gynecol Oncol; 2001 Sep; 82(3):489-97. PubMed ID: 11520145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Splenectomy and surgical cytoreduction for ovarian cancer.
    Chen LM; Leuchter RS; Lagasse LD; Karlan BY
    Gynecol Oncol; 2000 Jun; 77(3):362-8. PubMed ID: 10831343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach.
    Chi DS; Franklin CC; Levine DA; Akselrod F; Sabbatini P; Jarnagin WR; DeMatteo R; Poynor EA; Abu-Rustum NR; Barakat RR
    Gynecol Oncol; 2004 Sep; 94(3):650-4. PubMed ID: 15350354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Secondary cytoreductive surgery including rectosigmoid colectomy for recurrent ovarian cancer: operative technique and clinical outcome.
    Bristow RE; Peiretti M; Gerardi M; Zanagnolo V; Ueda S; Diaz-Montes T; Giuntoli RL; Maggioni A
    Gynecol Oncol; 2009 Aug; 114(2):173-7. PubMed ID: 19482344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thoracoscopy for the management of advanced epithelial ovarian cancer--a preliminary report.
    Eisenkop SM
    Gynecol Oncol; 2002 Feb; 84(2):315-20. PubMed ID: 11812093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A laparoscopy-based score to predict surgical outcome in patients with advanced ovarian carcinoma: a pilot study.
    Fagotti A; Ferrandina G; Fanfani F; Ercoli A; Lorusso D; Rossi M; Scambia G
    Ann Surg Oncol; 2006 Aug; 13(8):1156-61. PubMed ID: 16791447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective study of the correlation between postoperative computed tomography scan and primary surgeon assessment in patients with advanced ovarian, tubal, and peritoneal carcinoma reported to have undergone primary surgical cytoreduction to residual disease 1 cm or less.
    Chi DS; Ramirez PT; Teitcher JB; Mironov S; Sarasohn DM; Iyer RB; Eisenhauer EL; Abu-Rustum NR; Sonoda Y; Levine DA; Brown CL; Aghajanian C; Gershenson DM; Hoskins WJ; Hricak H; Barakat RR
    J Clin Oncol; 2007 Nov; 25(31):4946-51. PubMed ID: 17971592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aggressive surgical strategies in advanced ovarian cancer: a monocentric study of 203 stage IIIC and IV patients.
    Colombo PE; Mourregot A; Fabbro M; Gutowski M; Saint-Aubert B; Quenet F; Gourgou S; Rouanet P
    Eur J Surg Oncol; 2009 Feb; 35(2):135-43. PubMed ID: 18289825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of video-assisted thoracic surgery (VATS) in patients with suspected advanced ovarian malignancies and pleural effusions.
    Juretzka MM; Abu-Rustum NR; Sonoda Y; Downey RJ; Flores RM; Park BJ; Hensley ML; Barakat RR; Chi DS
    Gynecol Oncol; 2007 Mar; 104(3):670-4. PubMed ID: 17150248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ovarian cancer surgical resectability: relative impact of disease, patient status, and surgeon.
    Aletti GD; Gostout BS; Podratz KC; Cliby WA
    Gynecol Oncol; 2006 Jan; 100(1):33-7. PubMed ID: 16153692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.